Huntington's disease is a genetic neurodegenerative disorder characterized clinically by both motor and cognitive impairments and striatal lesions. At present, there are no pharmacological treatments able to prevent or slow its development. In the present study, we report the neuroprotective effect of adenosine amine congener (ADAC), a specific A 1 receptor agonist known to be devoid of any of the side effects that usually impair the clinical use of such compounds. Remarkably, in a rat model of Huntington's disease generated by subcutaneous infusion of the mitochondrial inhibitor 3-nitropropionic acid (3NP), we have observed that an acute treatment with ADAC (100 g ⅐ kg Ϫ1 ⅐ d Ϫ1 ) not only strongly reduces the size of the striatal lesion (Ϫ40%) and the remaining ongoing striatal degeneration (Ϫ30%), but also prevents the development of severe dystonia of hindlimbs. Electrophysiological recording on corticostriatal brain slices demonstrated that ADAC strongly decreases the field EPSP amplitude by 70%, whereas it has no protective effect up to 1 M against the 3NP-induced neuronal death in primary striatal cultures. This suggests that ADAC protective effects may be mediated presynaptically by the modulation of the energetic impairment-induced striatal excitotoxicity. Altogether, our results indicate that A 1 receptor agonists deserve further experimental evaluation in animal models of Huntington's disease.
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Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by both motor and cognitive symptoms . HD is caused by a mutation located within the IT15 gene, encoding for the Huntingtin protein, leading to an abnormal (CAG)n repeat in the 5Ј coding sequence (The Huntington's Disease Collaborative Research Group, 1993) . Histologically, this produces the formation of neuronal intranuclear inclusions (DiFiglia et al., 1997) and, for unclear reasons, the preferential loss of the striatal GABAergic projecting medium-sized spiny neurons (Vonsattel et al., 1985; Sieradzan and Mann, 2001) . Despite recent promising advances in the fields of cellular and gene therapies (Hantraye et al., 1992; Emerich et al., 1997; Palfi et al., 1998; Bachoud-Levi et al., 2000; Mittoux et al., 2000; De Almeida et al., 2001) , there are no available therapeutic tools to delay the onset of the symptoms and the associated neurodegeneration.
The striatal bioenergetic impairment suggested to occur in HD is thought to cause deleterious secondary excitotoxicity . Consistently, neurotoxicity of systemic administration of 3-nitropropionic acid (3NP), an irreversible inhibitor of succinate dehydrogenase known to produce striatal lesions in rats and nonhuman primates (Beal et al., 1993; Brouillet et al., 1995 Brouillet et al., , 1998 Brouillet et al., , 1999 Palfi et al., 1996; Dautry et al., 1999) , has been thought to involve glutamate neurotoxicity (Beal et al., 1993; Schulz et al., 1996; Guyot et al., 1997a) . Interestingly, in addition to the striatal lesion, 3NP also produces other features of HD such as movement (chorea, dystonia) and cognitive (perseveration) disorders, specific loss of spiny projection neurons and sparing of NADPH-diaphorase-expressing cells (Beal et al., 1993; Guyot et al., 1997a; Vis et al., 1999; El Massioui et al., 2001) .
Adenosine is a purinergic messenger known to reduce neuronal activity through activation of high-affinity receptors Dunwiddie and Masino, 2001 ). Many studies previously reported the neuroprotective properties of adenosine, and more especially of A 1 receptor agonists, in ischemic/hypoxic or epileptic conditions (Rudolphi et al., 1992; De Mendonca et al., 2000; Dunwiddie and Masino, 2001 ). These neuroprotective effects are thought to be related to the inhibitory function that presynaptic A 1 receptors exert on the release of excitatory amino acids, restraining, in particular, the activation of NMDA receptors (Fredholm and Dunwiddie, 1988; Palmer and Stiles, 1995) . Unfortunately, the potential therapeutic use of A 1 adenosine agonists is particularly impaired by cardiovascular side effects (Williams, 1993; White et al., 1996) , and the opposite outcome is observed after acute and chronic regimen (Von Lubitz et al., 1994a,b; De Sarro et al., 1996; Jacobson et al., 1996) ; however, some A 1 receptor agonists, devoid of any deleterious cardiovascular effects, have been described recently (Bischofberger et al., 1997) . Interestingly, among them it was shown that low concentrations of adenosine amine congener (ADAC) (Von Lubitz et al., 1996a,b) can efficiently protect hippocampal neurons against cerebral ischemia after both acute and chronic treatments (Von Lubitz et al., 1999) . This attractive compound thus deserves evaluation, especially in HD models for which A 1 receptor agonists have never been evaluated.
Recently, it was reported that Lewis rats, unlike the Sprague Dawley strain, respond homogeneously to 3NP and develop topologically reproducible striatal lesions, providing a suitable HD model for neuroprotective studies Blum et al., 2001 Blum et al., , 2002 Mittoux et al., 2002) . In the present work, we thus aimed to determine the potential neuroprotective effect of either chronic or acute treatment with the A 1 receptor agonist ADAC against the striatal lesions induced by 3NP in Lewis rats.
MATERIALS AND METHODS Animals
Adult male Lewis rats (I FFA Credo, Reims, France), 12 weeks of age, weighing 320 -380 gm were used in this study. Animals were housed three per cage and maintained in a temperature-and humidity-controlled room on a 12 hr light /dark cycle with food and water ad libitum. The number of animals was kept to the minimum, and all efforts to avoid animal suffering were made in accordance with the standards of the Institutional Ethical Committee of the School of Medicine of Université Libre de Bruxelles.
Surgery and 3NP treatment
Rats were anesthetized with a mixture containing xylazine hydrochloride (Rompun, Bayer; 4.5 mg / kg) and ketamine hydrochloride (Imalgene, Merial; 90 mg / kg). In the 3N P-treated animals, an incision was made below the base of the neck and a 2mL1 Alzet osmotic minipump (delivering 10 l / hr for 7 d; I FFA Credo) containing 3-nitropropionic acid (Fluka) was positioned under the skin. 3N P was dissolved in 0.1 M PBS, pH 7.4, adjusted to pH 7.3-7.4 with 5N NaOH. The final concentration of 3N P in the pump was adjusted to the weight of the rats on the day of implantation to exactly deliver 56 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 . Sham rats and animals treated with ADAC alone underwent all of the surgical procedures (without minipump implantation).
All rats were killed after 5 d of 3NP subcutaneous inf usion. It is noteworthy that the time they were killed was chosen according to the known kinetics of striatal lesion occurrence in this particular model, because it was determined previously that macroscopic lesions induced by 3N P are detected 5 d after the beginning of the toxic treatment Blum et al., 2001) .
ADAC treatment
T wo separate experiments were performed (Fig. 1) . In the first one, 28 rats (sham, n ϭ 7; vehicle/3N P, n ϭ 7; ADAC Ϫ8/5 , n ϭ 7; ADAC Ϫ8/5 / 3N P, n ϭ 7) were used to study the potential protective effect of chronic administration of ADAC against the neurotoxic effects of 3N P. In this protocol, ADAC injections began 8 d before the onset of 3N P intoxication and were continued until the animals were killed (13 d in all; last injection 6 hr before animals were killed). ADAC solution was prepared as follows: 6 mg of ADAC (Sigma) were first dissolved in 200 l of 1N HC l and then added to 120 ml of 0.1 M PBS, pH 7.4, to reach a final concentration of 50 g /ml. Before each injection, the solution was heated to 37°C for 15-30 min to ensure complete dissolution. Vehicle solution (200 l of 1N HC l in 120 ml of 0.1 M PBS) was processed similarly. The final pH of all solutions was 7.3-7.4. The volume of the ADAC solution injected intraperitoneally was adjusted to the weight of rats to deliver exactly 100 g ⅐ kg Ϫ1 ⅐ d Ϫ1 (200 l /100 gm of weight), a supramaximal dose that has been shown previously to be protective against cerebral ischemia after both chronic and acute administration (Von L ubitz et al., 1999) without any cardiovascular side effects (Von L ubitz et al., 1996b) .
In the second experiment, 50 rats were used to study the potential neuroprotective effects of acute treatments with ADAC (sham, n ϭ 7; 3N P/ vehicle, n ϭ 9; ADAC alone injected at days 3, 4, and 5 ϭ ADAC 3/5 group, n ϭ 7; 3N P-treated rats injected with ADAC at days 3, 4 and 5 ϭ 3N P/ADAC 3/5 , n ϭ 10; ADAC alone injected at days 4 and 5 ϭ ADAC 4/5 group, n ϭ 7; 3N P-treated rats injected with ADAC at days 4 and 5 ϭ 3N P/ADAC 4/5 , n ϭ 10). ADAC injections were performed as described above (last injection 6 hr before animals were killed).
Tissue post-processing
All rats were killed by decapitation, and their brains were quickly removed. The two cerebral hemispheres were separated. One was frozen in 2-methylbutane cooled by dry ice (Ϫ40°C), and the other was embedded in paraffin. The frozen tissue was cut at 16 m thickness on a cryostat (Leitz), and the serial coronal sections were mounted onto poly-L-lysine or gelatin-coated slides and stored at Ϫ20°C until use. Paraffin-embedded brains were cut at 10 m using a microtome (Historange), and the coronal sections were mounted on gelatin-coated slides in glutamine albumin (BDH Chemicals, Poole, UK) for immunohistochemistry.
Behavioral analysis
Controls and 3N P-treated animals were evaluated every day for both weight loss and motor impairment. For the latter, we used a quantitative neurological scale as described previously (Guyot et al., 1997a; Blum et al., 2001 Blum et al., , 2002 Mittoux et al., 2002) . Briefly, behavioral abnormalities were determined according to the presence and severity of motor symptoms consisting of dystonia (intermittent dystonia of one hindlimb, score ϭ 1; intermittent dystonia of two hindlimbs, score ϭ 2; permanent dystonia of hindlimbs, score ϭ 3), gait abnormalities consisting mainly of an uncoordinated and wobbling gait (score ϭ 1), and recumbency (animals lying on one side but showing uncoordinated movements when stimulated, score ϭ 1; near-death recumbency characterized by almost complete paralysis with rapid breathing, score ϭ 2). Additionally, the capabilities of animals to grasp a cage grid with forepaws (unable ϭ 1) or to remain on a small platform (9 ϫ 5 cm) for Ͼ10 sec (unable ϭ 1) were determined. The final neurological score was assessed as the sum of the above individual scores (minimum ϭ 0, normal animal; score ϭ 8, animal showing near-death recumbency).
NeuN immunohistochemistry
Paraffin sections were successively dipped in toluol and 100% alcohol. After quenching of endogenous peroxidases (0.3% hydrogen peroxide in methanol for 30 min), sections were rehydrated by 90 and 70% ethanol and then water. After a 10 min microwave treatment in citrate buffer (0.01 M, pH 6), slides were rinsed in PBS and incubated for 10 min in 10% normal horse serum (Invitrogen). Sections were then incubated overnight at 4°C with mouse monoclonal anti-NeuN antibody [1:300 in 1% normal horse serum (Chemicon, Temecula, CA) M AB377]. After two washes, they were incubated f urther for 15 min with 10% normal horse serum and then for 30 min with biotinylated donkey anti-mouse secondary antibody (1:200 in 1% normal horse serum; Jackson ImmunoResearch, West Grove, PA). After two washes, the signal was revealed by the ABC method (Vector Laboratories) and diaminobenzidine (Dako). 
Terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling staining
Detection of nuclei presenting DNA-strand breaks was obtained by the terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUN EL) method. Frozen sections mounted on poly-Llysine-coated slides were postfixed for 30 min in 4% paraformaldehyde, rinsed three times in PBS, and successively treated at room temperature by a 0.1% citrate and 1% Triton X-100 buffer for 5 min, rinsed in PBS, and incubated for an additional 5 min with proteinase K (10 g /ml in PBS, pH 7.4). TUN EL reaction (30 min at 37°C) was performed using a commercial kit according to the manufacturer's instructions (Roche). Positive-labeled cells were observed under epifluorescence using a Z eiss microscope connected to an acquisition system. Quantification of TUN EL -positive cells was performed at 40ϫ magnification on four digitalized fields located in the dorsolateral part of the striatum at the level of bregma approximately ϩ0.48 mm according to the atlas of Paxinos and Watson (1990) (Fig. 2) [region of interest 2 (ROI 2)].
Semiquantitative measurement of succinate dehydrogenase activity
Measurement of succinate dehydrogenase (SDH) activity in control and 3N P-treated rats was performed as described previously . Frozen sections mounted on poly-L-lysine-coated slides were air dried and then incubated for 15 min in 0.1 M PBS (pH 7.4, 0.9% NaC l) at 37°C followed by incubation in 0.3 mM nitroblue tetrazolium (Sigma), 0.05 M sodium succinate (Sigma), and 0.05 M phosphate buffer, pH 7.6, for 30 min at 37°C. Finally, sections were rinsed successively for 5 min in cold PBS and deionized water and dried at room temperature. The image of each section was acquired, and the quantification was performed as described previously Blum et al., 2001 ) using N IH image software according to the ROIs (1-3 and 5) presented in Figure 2 . Results were expressed as the percentage mean Ϯ SEM of mean sham value.
Enkephalin mRNA in situ hybridization
The hybridization technique was adapted from previous reports from our lab (Schiffmann and Vanderhaeghen, 1993; Dassesse et al., 1999) . The sections mounted on RNase free poly-L-lysine-coated slides were fixed in 4% freshly prepared paraformaldehyde for 30 min and rinsed in 0.1 MM PBS. All sections were dehydrated and dipped for 3 min in chloroform. After air drying, the sections were incubated overnight at 42°C with 0.35 ϫ 10 6 cpm per section of 35 S-labeled probes diluted in hybridization buffer, which consisted of 50% formamide, 4ϫ SSC (1ϫ SSC: 0.15 M NaC l, 0.015 M sodium citrate, pH 7.4), 1ϫ Denhardt's solution (0.02% each of poly vinylpyrrolidone, bovine serum albumin, Ficoll), 1% sarcosyl, 0.02 M sodium phosphate at pH 7.4, 10% dextran sulfate, yeast tRNA at 500 g /ml, salmon sperm DNA at 100 g /ml, and 60 mM dithiothreitol. Compounds were provided by Sigma. After hybridization, the sections were rinsed for 4 ϫ 15 min in 1ϫ SSC at 55°C, dehydrated, and covered with Hyperfilm-␤max film (Amersham) for 2 or 3 weeks. The oligonucleotide enkephalin probe (5Ј-GTGTGCATGCCAGGAAGTTGATGT-CGCCGGGACGTACCAGGCGG-3Ј) was synthesized on an Applied Biosystems 381A DNA synthesizer. It was labeled with ␣-35 S dATP (DuPont N EN) at its 3Ј end by terminal DNA deoxynucleotidylexotransferase (Invitrogen) and purified with a G50 column (Pharmacia Biosciences) according to the manufacturer's instructions.
In vitro receptor autoradiography
A 1 receptor binding autoradiography was performed as described previously (Dassesse et al., 2001 ) using a single concentration of radioligand. The gelatin-coated slides, stored at Ϫ20°C until use, were brought to room temperature 30 min before the autoradiographic experiments.
The sections were preincubated for 30 min at 37°C in preincubation buffer [170 mM Tris-HC l, pH 7.4, 1 mM EDTA, 2 UI /ml adenosine deaminase (ADA)] and incubated for 2 hr at room temperature in buffer containing 170 mM Tris-HC l, pH 7.4, 1 mM MgC l 2 , 2 UI /ml ADA, and 0.5 nM of the A 1 antagonist [
3 H]-8-cyclopentyl-1,3-dipropylxanthine (DPC PX) (120.0 C i /mmol; DuPont N EN). Nonspecific binding of the 3 H-labeled ligand was assessed by the addition of 20 M R(Ϫ)N 6 -2-phenylisopropyladenosine (R-PIA). Slides were washed three times for 15 min in ice-cold 170 mM Tris-HC l, pH 7.4 buffer, dipped in ice-cold distilled water, dried under a stream of cold air, and exposed to 3 HHyperfilms (Amersham) for 6 weeks.
Image analysis
Digitalized images with 256 gray levels were generated from the autoradiograms with the public domain N IH image 1.61 program (National Institutes of Health, Bethesda, MD), a Power Macintosh G3, and a CCD video camera (Dage-MTI) with fixed gain and black level. For the quantification of in situ hybridization and binding, depending on the marker studied, the average optical densities were measured on x-ray film autoradiograms in three different striatal regions (ROIs 1, 2, and 3) (Fig.  2 ) and in the overlying cortex (ROI 6) (Fig. 2) . For in situ hybridization analysis, on each section an averaged optical density of the background level was subtracted from that of the measured areas to obtain corrected values. For quantification of binding autoradiography, specific binding was determined by subtracting the nonspecific from the total binding. Analyses were performed at the transverse level ϳ0.48 mm rostral to bregma, according to the rat brain atlas of Paxinos and Watson (1990) . Results were expressed as the percentage mean Ϯ SEM of mean sham value.
Electrophysiology
Electrophysiological experiments were performed as described previously (D'Alcantara et al., 2001) . Wistar rats (15-30 d old) were used (n ϭ 5). Neostriatal slices were prepared as follows. Animals were anesthetized with ether and decapitated. The brain was immediately removed, transferred to ice-cold modified Krebs' solution, and cut in coronal blocks that were then glued to the stage of a Vibratome (Leica) with cyanoacrylate glue. The composition of the solution was (in mM): 124 NaC l, 3 KC l, 1.2 NaH 2 PO 4 , 1 MgC l 2 , 2 CaCl 2 , 10 glucose, and 26 NaHC O 3 , and it was gassed continuously with a 95% O 2 , 5% CO 2 mixture. Coronal slices (300 m) taken ϳ0.48 mm rostral to the bregma according to the brain atlas of Paxinos and Watson (1990) were cut from these tissue blocks. Slices were allowed to recover for Ն1 hr in the same oxygenated solution at 32-34°C before recording. A single slice was transferred to a recording chamber (3-4 ml volume) and submerged in a continuously flowing extracellular solution (21-24°C, 2-3 ml /min) gassed with a 95% O 2 , 5% CO 2 mixture. For recording, this modified Krebs' solution also contained 25 M picrotoxin, a GABA receptor antagonist, to isolate excitatory potentials. The slices were allowed to f urther recover for 30 -60 min at room temperature in the picrotoxin-containing solution before the recording procedure was started. Standard field potential recording techniques were used. Electrodes (2-8 M⍀) pulled out from borosilicate capillaries were filled with the same solution without picrotoxin. E xtracellular potentials were amplified using a World Precision Instrument DAM 80 amplifier, displayed on an oscilloscope, and digitized using the Bio-logic L M-200 interface. Slices were stimulated by a 50 sec current pulse delivered through bipolar tungsten electrodes and controlled by a Master 8 pulse generator (AM PI). The stimulation electrode was located in the dorsolateral striatum close to the recording electrode (0.2-1.5 mm). For all experiments, data were filtered at 1 kHz, digitized at 6 -7 kHz, and collected using the Bio-logic Acquis1 acquisition program, which provided an on-line analysis of the amplitude of the rising phase of the field EPSP (fEPSP). Stimuli were given at 0.1 Hz, and points on the illustrated figures represent the means of data collected Figure 2 . Schematic drawing showing the ROIs (1-6 ) delimited for quantification: 1, whole striatum; 2, dorsolateral striatum; 3, dorsomedial striatum; 4, ventrolateral striatum; 5, outer layers of the cortex; 6, overlying cortex.
from all traces in bins of 1 min. In electophysiological protocols, the input stimulation was calibrated to obtain half-maximal fEPSP. Numerical data were expressed as mean Ϯ SEM. Depending on experimental protocols, the extracellular solution was modified by addition of ADAC (diluted at the same concentration as for in vivo experiments, i.e., 50 g /ml, ϳ86 M).
Cell culture, treatments, and viability assay
Primary cultures of striatal neurons were obtained from 17-to 18-d-old Wistar rat embryos and prepared as described (Schiffmann et al., 1998) . C ells were cultured in Neurobasal medium supplemented with B27 containing 200 mM glutamine. C ells were treated with 3N P at 7 DIV. ADAC treatment (10 Ϫ 2 M stock solution in DMSO, diluted in culture medium) was performed 60 min before the addition of 3N P. C ell viability was assessed by MTT assay, 3 d after 3N P treatment as follows. C ells were cultured for 4 hr in the presence of MTT (5 mg /ml; Sigma). The reaction was stopped by adjunction of DMSO. The optical density was measured at a wavelength of 540 nm on a Titertek Multiskan MCC /340 (IC N Biomedicals, Costa Mesa, CA).
Determination of protein kinase A activity
In vivo treatments. Lewis rats (12 weeks old) were treated either by vehicle (n ϭ 3) or by one daily injection of ADAC for 3 d (n ϭ 3). As a control for desensitization, one rat was chronically treated with ADAC for 13 d. At the end of treatments, animals were killed by decapitation. Their striata were dissected out and homogenized with a glass tissue blender in 10 vol of ice-cold extraction buffer (25 mM Tris-HC l, pH 7.4, 1 mM EDTA, 1 mM DTT) containing a protease inhibitor mixture (Complete, Roche Molecular Biochemicals, Mannheim, Germany). Forskolin (10 Ϫ 4 M) was incubated with striatal homogenates for 10 min at 30°C. ADAC (10 Ϫ 5 M) treatment of the homogenates was started 10 min before incubation with forskolin.
In vitro treatments. Striatal neurons were treated with forskolin (10
M) for 1 hr at 37°C in a 5% CO 2 atmosphere. ADAC (10 Ϫ 6 M) treatment was started 30 min before this incubation. C ells were then washed with warm PBS and homogenized in lysis buffer (M-PER, Pierce, Rockford, IL; 6 ϫ 10 6 cells in 400 l) containing a protease inhibitor mixture (Complete, Roche Molecular Biochemicals).
Protein k inase A assay. Soluble extracts from rat striata or striatal neurons were separated by centrif ugation (15,000 ϫ g, 10 min, 4°C), and the protein concentration was determined using MicroBCA Protein Assay (Pierce). PepTag assay for nonradioactive detection of cAM Pdependent protein kinase was performed consistently following the manufacturer's instructions (Promega, Madison, W I). Briefly, all reaction components were combined on ice, and protein kinase A (PK A) activity was assayed at 30°C for 30 min, in a final volume of 25 l of the following mixture: 5 l of reaction buffer, 5 l (0.4 g/l) f-kemptide, 1 l of anti-protease solution, and sample striatal extract (2 g protein) or sample neuron lysate (10 g protein). For each condition, reactions were performed in triplicate. Reactions were stopped after 30 min by placing the tubes in a water bath at 95°C for 10 min and then either immediately loaded for electrophoresis or frozen at Ϫ20°C until use. Samples were loaded on a 0.8% agarose gel prepared in 50 mM Tris buffer, pH 8.0. The electrophoresis was run at 100 V for 30 min. Resulting separation was observed under UV light and acquired using a CDD camera. Optical density of the bands was measured using N IH image software, and the results were expressed as the ratio of phosphorylated over nonphosphorylated peptide.
Electrophoresis and immunoblotting
Protein electrophoresis was performed as described previously (Galas et al., 2000) . Briefly, cells were homogenized in lysis buffer (M-PER, Pierce) containing a protease inhibitor mixture (Complete, Roche Molecular Biochemicals) (6 ϫ 10 6 cells in 500 l). Samples were stored at Ϫ20°C until they were analyzed. Protein concentration was determined using MicroBCA Protein Assay (Pierce). Equal amounts of proteins (10 g) were denaturated in 2ϫ Laemmli buffer at 100°C for 5 min and then separated on 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose (Bio-Rad, Hercules, CA) at 250 mA for 90 min at 4°C. The membrane was blocked with 5% BSA, 0.1% T ween 20 in PBS buffer containing 2% goat serum and then incubated with the primary antibody (anti-A 1 receptor, A 1 R11-A, 1:1000; Alpha Diagnostic, San Antonio, TX) overnight at 4°C. After washing in PBS buffer containing 0.1% T ween 20, the membrane was incubated with the HRP-labeled secondary antibody (goat anti-rabbit IgG; DuPont N EN, Boston, M A) at a concentration of 0.1 g /ml for 60 min at room temperature. Immunoreactive bands were visualized by chemiluminescent ECL Plus Western blotting detection reagents (Amersham, Buckinghamshire, UK). A control experiment performed without the primary antibody demonstrated the absence of signal at the molecular weight corresponding to A 1 receptor (data not shown).
Analysis and statistics
Results were expressed as means Ϯ SEM. Depending on the parameter studied, comparisons among groups were made using either MannWhitney or Kruskal -Wallis/ Dunn nonparametric tests, the unpaired t test, the Fisher test with Yates correction, or one-way ANOVA followed by a Newman -Keuls post hoc test. Electrophysiological data were analyzed by a paired t test (GraphPad Software).
RESULTS

Effects of ADAC on 3NP-induced motor deficits Chronic treatment
The first 2 d after minipump implantation, animals did not present any behavioral changes (Fig. 3A) . Disabilities began the third day, and the evolution of motor symptomatology was similar in the vehicle/3NP and the ADAC Ϫ8/5 /3NP groups (Fig. 3A) . At day 3, three of seven and four of seven rats were clinically affected in the vehicle/3NP and the ADAC Ϫ8/5 /3NP groups, respectively, with animals presenting slight intermittent dystonia of one hindlimb and gait abnormalities. The following day (day 4), motor impairments worsened. In both groups, all animals were clinically affected and shared gait abnormalities. Rats presented either pronounced dystonia of one hindlimb or intermittent dystonia of both hindlimbs. After 5 d of subcutaneous infusion of 3NP, all of the rats were alive and homogeneously clinically affected with strong impairment of locomotor activity (Fig. 3A, Table 1 ). Permanent dystonia of both hindlimbs was observed in six of seven or five of seven rats in the vehicle/3NP or the ADAC Ϫ8/5 /3NP groups, respectively. In both groups, inability to remain on the platform for a short time was observed in six of seven rats; among them, two were recumbent. Neurological symptoms were accompanied with pronounced weight loss, reaching 17-18% at day 5 (Table 1) . Therefore, motor disabilities as well as weight loss were similar in the 3NP group of rats chronically treated or not with ADAC (Fig. 3A, Table 1 ). The neurological score of the sham animals as well as the rats chronically treated with ADAC alone was always of zero.
Acute treatments
Behavioral changes observed in the 3NP/vehicle-treated rats were essentially similar to those described above (Fig. 3B , Table  1 ). At day 3, five of nine rats were clinically affected, with animals presenting gait abnormalities. At day 4, all animals were clinically affected and shared gait abnormalities. Seven of nine rats presented intermittent dystonia of both hindlimbs. At day 5, all rats (nine of nine) were alive (Fig. 3B, Table 1 ). Permanent dystonia of both hindlimbs and inability to remain on the platform were observed in all rats, and seven of nine were recumbent (Table 1) . 3NP rats acutely treated by ADAC 4 and 5 d after minipump implantation were relatively spared (3NP/ADAC 4/5 group) (Fig.  3B , Table 1 ). Indeed, although evolution of motor symptomatology was similar to that of 3NP/vehicle group from days 1-4, at day 5 all of these rats (10 of 10) had a neurological score of 3 (Fig.  3B , Table 1 ), and none of them (0 of 10) presented either permanent dystonia of both hindlimbs or recumbency (Table 1) . They were all (10 of 10) able to remain on the platform for Ͼ10 Figure 4 . Histological evaluation of the neuroprotection induced by ADAC in 3NP-treated rats. A, Typical hematoxylin staining of section for a rat treated by 3NP alone or after a chronic treatment with ADAC (ADAC Ϫ8/5 /3NP group). B, Typical hematoxylin staining of a section from a rat treated with 3NP alone or after acute treatments with ADAC (3NP/ADAC 3/5 and 3NP/ADAC 4/5 groups). C, D, Quantification of the striatal lesion size at the ϩ0.48 mm stereotaxic plane represented in A and B, respectively. **p Ͻ 0.01 using Newman-Keuls ANOVA post hoc test versus 3NP-treated rats. OEOEOE p Ͻ 0.001 using Newman-Keuls ANOVA post hoc test versus 3NP/ADAC 3/5 -treated rats. sec, and their motor impairment consisted only of intermittent dystonia of both hindlimbs. Additionally, the mean weight loss of 3NP/ADAC 4/5 group was lower than for the 3NP/vehicle animals (Table 1) . Conversely, although only 6 of 10 animals presented permanent dystonia of both hindlimbs and the weight loss was slightly lower than for 3NP/vehicle animals, behavioral alterations observed at day 5 in the 3NP/ADAC 3/5 group were not significantly different from the 3NP/vehicle group (Fig. 3B, Table  1 ). As in the first experiment, ADAC alone did not alter body weight or motor behavior (data not shown).
Effects of ADAC on 3NP-induced striatal lesion Chronic treatment
In the 3NP-treated rats of the first experiment, macroscopic analysis of hematoxylin-stained sections confirmed the presence of a large striatal pale area topologically restricted to the lateral striatum (surface of 8.2 Ϯ 0.6 mm 2 at the stereotaxic plane approximatively ϩ0.48 mm) (Fig. 4 A, C) . The surface of this striatal lesion (7.95 Ϯ 0.45 mm 2 ) was not modified in rats chronically treated with ADAC (ADAC Ϫ8/5 /3NP group) (Fig. 4 A, C) .
Acute treatments
In the 3NP-treated rats of the second experiment, the surface of the striatal lesion was 11.3 Ϯ 0.6 mm 2 at the stereotaxic plane approximatively ϩ0.48 mm (Fig. 4 B, D) . The surface of the lesion core was significantly reduced by 41.2 Ϯ 7.1% in the 3NP/ ADAC 4/5 group (Fig. 4 B, D) . Conversely, it was not modified in the 3NP/ADAC 3/5 group (Fig. 4 B, D) . Neither chronic nor acute injections of ADAC alone induced striatal histological alterations (data not shown). It is noteworthy that in the protected group, the lesion core was less extended to the ventral part of the striatum when compared with 3NP animals (Fig. 4 B) . Similar results were found when we measured the volume of the lesion core in the anterior part of the striatum (bregma approximately ϩ1.4 mm to bregma approximately Ϫ0.2 mm using Cavalieri's principle on sections separated by 320 m intervals). Indeed, we found a value of 15.2 Ϯ 0.5 mm 3 for the 3NP-treated rats. The volume of the lesion core was significantly reduced by 30 Ϯ 6% in the 3NP/ ADAC 4/5 group (10.6 Ϯ 1 mm 3 ; p Ͻ 0.05; Newman-Keuls post hoc test vs 3NP group). Conversely, it was not modified in the 3NP/ADAC 3/5 group (17.3 Ϯ 1.7 mm 3 ; NS; Newman-Keuls post hoc test vs 3NP group).
Effects of ADAC on 3NP-induced succinate dehydrogenase inhibition
Because SDH is a well known irreversible target for 3NP , we aimed to determine whether ADAC treatment could interfere with the 3NP-induced complex II inhibition. Semiquantitative histochemical measurements showed that 3NP greatly decreased SDH activity in both the striatum (ROI 1) (Fig. 2) and the outer cortical layers (ROI 5) (Fig. 2) , with the higher alteration in the former (Fig. 5 A, B) . In the 3NP/ADAC 4/5 group, striatal enzymatic activity was slightly but significantly increased when compared with 3NP/vehicle animals, whereas 3NP-induced SDH inhibition was similar in the cortex (Fig. 5B) . Striatal and cortical SDH activity impairment was not modified by a chronic treatment with ADAC or within the 3NP/ ADAC 3/5 group (Fig. 5 A, B) . It should also be noted that ADAC alone did not modify basal SDH activity in any of the conditions tested (data not shown).
Striatal and cortical effects of ADAC on the density of A 1 receptor binding sites
To determine whether the lack of striatal protection observed after chronic administration or in the 3NP/ADAC 3/5 group was caused by downregulation of the adenosine A 1 receptors, binding experiments were performed in rats treated with the agonist alone (ADAC Ϫ8/5 , ADAC 3/5 , and ADAC 4/5 groups). As shown in Figure 6 , chronic ADAC treatment dramatically decreased the density of [ 3 H]-DPCPX binding sites, reaching 60.9 Ϯ 10.6 and 73.9 Ϯ 4.9% in the striatum (ROI 1) and the overlying cortex (ROI 6), respectively (Fig. 6 A, B) . It is noteworthy that the [ 3 H]-DPCPX binding signal observed in the ADAC Ϫ8/5 group is higher than the nonspecific binding level, itself indistinguishable from the film background (Fig. 6 A) . In opposition to chronic treatment, in acute conditions ADAC did not significantly modify the density of [ 3 H]-DPCPX binding sites (Fig. 6C,D) . To determine whether the lack of protective effects of ADAC in the 3NP/ADAC 3-5 group was not caused by a functional desensitization of the A 1 receptor, we have tested the efficacy of A 1 receptor activation to inhibit the forskolin-induced activation of PKA in brain homogenates from rats treated with vehicle, with ADAC for 3 d, or, as a control of desensitization, with ADAC for 13 d. We found that in vehicle rats, forskolin induced PKA activation to 155.2 Ϯ 9.4% of the control value ( p Ͻ 0.05 vs control; Newman-Keuls post hoc test). This increase was reduced to 100.4 Ϯ 18.6% of the control value in the presence of ADAC Figure 5 . Determination of succinate dehydrogenase activity in the striatum and the cortex of 3NP-treated rats and animals receiving chronic ( A) or acute ( B) treatment with ADAC. ***p Ͻ 0.001, **p Ͻ 0.01 using Newman-Keuls ANOVA post hoc test versus sham rats.
OEOEOE p Ͻ 0.001 using Newman-Keuls ANOVA post hoc test versus 3NP/Vehicle or 3NP/ADAC 3/5 -treated rats.
( p Ͻ 0.05 vs forskolin and NS vs control; Newman-Keuls post hoc test), although the agonist alone did not share a significant effect by itself in the absence of forskolin (104.9 Ϯ 5% of the control; NS; Newman-Keuls post hoc test). In accordance with the binding experiment, after a chronic treatment with the agonist, we found that ADAC was unable to reduce the forkolin-induced PKA activation (data not shown). Similar results were found in rats treated with ADAC for 3 d. Indeed, in these rats, although forskolin induced PKA activity by 179 Ϯ 38% ( p Ͻ 0.01 vs control; Newman-Keuls post hoc test), in the presence of the agonist, PKA activity did not return to the basal level because it was still activated by 199 Ϯ 23% as compared with the control condition (NS vs forskolin condition; Newman-Keuls post hoc test). Consequently, it appears that a 3 d treatment with ADAC is sufficient to induce a functional desensitization of the A 1 receptor.
Histological and functional effects of acute ADAC 4/5 treatment on the striatal alterations induced by 3NP NeuN immunoreactivity and TUNEL staining
Using NeuN immunohistochemistry, we observed neuronal loss after 3NP treatment within both the dorsolateral and ventrolateral striatum (ROIs 2 and 4) (Fig. 7C,D) . In accordance with the limited extension of the lesion core toward the ventrolateral striatum (Fig. 4 B) , the neurons of 3NP/ADAC 4/5 -treated rats located within this area appeared healthy (Fig. 7F ) . Using TUNEL staining, we aimed to determine whether the remaining cells located within the lesion core (ROI 2) (Fig. 2) underwent ongoing DNA damage. In 3NP animals, the density of TUNELpositive cells was measured as 640 Ϯ 46 cells per millimeters squared. This density was significantly reduced by 29.7 Ϯ 7.7% in the lesion core of the 3NP/ADAC 4/5 group ( p Ͻ 0.01 vs 3NP group; unpaired t test) (Fig. 8) . ADAC is thus able to reduce not only the lesion size but also the ongoing striatal degeneration.
Enkephalin mRNA expression
Using in situ hybridization, we also quantified the expression of enkephalin mRNA, which is expressed by a subpopulation of the affected spiny neurons. As shown in Figure 9 , ADAC 4/5 reduced the loss of enkephalin mRNA expression observed after the 3NP treatment (Fig. 9 A, B) . Indeed, 3NP alone decreased the enkephalin mRNA level by 65 Ϯ 5.4%, whereas this reduction was lowered to 42 Ϯ 5.7% in the 3NP/ADAC 4/5 group (Fig. 9B) . It is noteworthy that the striatal surface presenting enkephalin mRNA depletion was strongly reduced in the 3NP/ADAC 4/5 group (stereotaxic plane approximatively ϩ0.48 mm) as compared with the 3NP rats and that ADAC alone did not modify basal enkephalin mRNA expression (data not shown).
Effect of ADAC on corticostriatal synaptic transmission
Because glutamate was suggested to be, at least in part, a component of striatal vulnerability to 3NP (Beal et al., 1993; Guyot et al., 1997b) , we aimed to determine whether ADAC, which has never before been evaluated by electrophysiology, would be able to modify glutamatergic corticostriatal transmission. In agreement with previous results obtained with other A 1 receptor ago- nists (Flagmeyer et al., 1997; D'Alcantara et al., 2001) , the fEPSP amplitude was markedly decreased after addition of ADAC (33 Ϯ 6% of the control value; n ϭ 5; p Ͻ 0.001) (Fig. 10) , and this effect was totally reversed by washing out this compound from the external solution.
Effects of ADAC on 3NP-induced striatal cell death in vitro
We finally aimed to determine whether the protective effect of ADAC could be related to an intrinsic effect involving A 1 receptors located on striatal cells. As shown in Figure 11 A, striatal neurons from primary cultures express A 1 receptors, confirming RT-PCR experiments (data no shown). Treatment of striatal cells with 75 M 3NP led to a significant reduction of neuronal viability (Fig. 11 B) . The 3NP concentration was chosen according to the dose-effect experiments that we performed, and we gave 75 M as the ED 50 in our cellular system (data not shown). ADAC alone did not significantly alter cellular viability (data not show), and this A 1 agonist did not modify the 3NP-induced cell death whatever the concentration (Fig. 11 B) .
Because it was reported previously that in immature rat brain the lack of a neuroprotective effect of ADAC may be caused by a functional uncoupling of the A 1 receptor (Aden et al., 2001 ), we measured the functional state of the latter in our culture system. We found that A 1 receptors were functionally and negatively coupled to adenylyl cyclase because ADAC, by itself, reduced basal PKA activation by 31.7 Ϯ 4.2% ( p Ͻ 0.001 vs untreated control; Newman-Keuls post hoc test). In the presence of forskolin, PKA activity was increased to 228.4 Ϯ 10.8% of the untreated control ( p Ͻ 0.05 vs untreated control; Newman-Keuls post hoc test), and this activation was reduced by 52.71 Ϯ 9.8% in the presence of ADAC ( p Ͻ 0.001 vs forskolin-activated cells; Newman-Keuls post hoc test).
DISCUSSION
At present, there are no pharmacological treatments for Huntington's disease despite first attempts with compounds such as riluzole or coenzyme Q10 (Beal et al., 1994; Guyot et al., 1997b; Palfi et al., 1997; The Huntington's Disease Study Group, 2001) and more recent promising studies evaluating dichloroacetate and creatine (Andreassen et al., 2001a,b; Tarnopolsky and Beal, 2001) . The most striking experimental and preclinical advances in the treatment of this neurodegenerative disorder have been obtained recently using cellular and gene therapy strategies (Hantraye et al., 1992; Emerich et al., 1997; Palfi et al., 1998; BachoudLevi et al., 2000; Mittoux et al., 2000 Mittoux et al., , 2002 De Almeida et al., 2001) . However, considering the technical complexity of such approaches, it remains important to test new drugs susceptible to display neuroprotective properties in this neurodegenerative disease.
In the present study, we report that treatment with a low dose of the A 1 receptor agonist ADAC protects Lewis rats from 3NP-induced striatal degeneration and motor disabilities. In particular, our results show that acute administration of ADAC on the day preceding the lesion (day 4) Blum et al., 2002 ) not only significantly decreases the size of the striatal lesion but also delays the ongoing cellular degeneration that occurs in the remaining lesion core. Also of great interest, ADAC efficiently slowed the worsening of motor disturbances, notably dystonia. To our knowledge, this is the first report suggesting the potential use of an A 1 receptor agonist in a model of HD, opening new possibilities for adenosinergic compounds. The beneficial potential of adenosine, and particularly of A 1 receptor agonists, in neurodegenerative disorders has already been suggested, especially for ischemia and epilepsy (Connick and Stone, 1989; Rudolphi et al., 1992; De Mendonca et al., 2000; Dunwiddie and Masino, 2001; Huber et al., 2001 ). Nevertheless, their clinical implementation was mitigated by cardiovascular and hypotensive side effects (Williams, 1993; White et al., 1996) . Recently, new classes of A 1 agonists, devoid of such disturbing issues, have been disclosed (Knutsen et al., 1995; Bischofberger et al., 1997) . Among them, ADAC has been studied extensively as a potential candidate for the treatment of ischemia (Von Lubitz et al., 1996a ,b, 1999 .
Our electophysiological data clearly demonstrate that ADAC powerfully inhibits striatal fEPSPs generated by the stimulation of cortical afferent fibers. This is in agreement with previous findings showing that presynaptic activation of A 1 receptors interferes with glutamate neurotransmission, thereby reducing AMPA-and NMDA-mediated field potentials (Malenka and Kocsis, 1988; De Mendonca et al., 1995; Flagmeyer et al., 1997; D'Alcantara et al., 2001) . It can thus be suggested that ADAC likely prevents striatal excitotoxicity generated by 3NP , without generating any behavioral side effects. This hypothesis is supported by several studies demonstrating the protective potency of NMDA antagonists against striatal neuro- pathology induced by quinolinic acid, malonate, or 3NP (Beal et al., 1993; Schulz et al., 1995 Schulz et al., , 1996 Jenkins et al., 1996) . At a cellular level, ADAC could then indirectly counteract the NMDA-mediated neuronal calcium overload induced by 3NP , thereby depressing the deleterious activation of detrimental enzymes such as nitric oxide synthase or calpain (Nishino et al., 1996; Bizat et al., 2001 ). Activation of neuronal postsynaptic A 1 receptors could also directly (Mogul et al., 1993) and indirectly (Trussell and Jackson, 1985) depress calcium influx. However, the lack of protection provided by ADAC against 3NP-induced striatal cell death in vitro, despite the presence of functional A 1 receptors, argues against this latter possibility. It has to be mentioned that electrophysiological and cell culture experiments have been performed on Wistar instead of Lewis rats. Although very unlikely, an effect of the strain difference therefore may not be ruled out.
Striatal 3NP toxicity also involves dopaminergic neurotransmission. Indeed, this neurotoxin increases the striatal dopamine overflow (Nishino et al., 1997; Johnson et al., 2000) that is responsible, at least in part, for the rise in intracellular calcium (Nishino et al., 1997) . Enhancing striatal dopamine release using methamphetamine or sulpiride potentiates 3NP neurotoxicity (Reynolds et al., 1998; Nishino et al., 2000) , whereas nigral lesions prevent it (Reynolds et al., 1998) . Given that stimulation of presynaptic A 1 receptors results in an inhibition of striatal dopamine release (Wood et al., 1989; Zetterstrom and Fillenz, 1990) , ADAC-mediated neuroprotection could also be attributed to A 1 receptor regulation at the nigrostriatal terminals.
A possible interaction between ADAC and 3NP limiting the access of the toxin to SDH was ruled out because our results indicate that both chronic and acute treatments with ADAC do not alleviate the 3NP-induced SDH inhibition in either the striatum or the cortex. The slight increase in SDH activity observed within the whole striatum in the 3NP/ADAC 4/5 group is likely attributable to the reduction of the lesion size rather than to a direct interaction between ADAC and 3NP, because we showed previously that the inhibition of SDH activity was greater within the lesion core after a 5 d subcutaneous infusion of 3NP (Blum et al., 2001 (Blum et al., , 2002 .
We did not observe any neuroprotective effects of ADAC in the chronic ADAC Ϫ8/5 /3NP or acute 3NP/ADAC 3/5 groups. It appears that a sustained administration of the A 1 receptor agonist (chronic condition) but also a 3 d treatment (ADAC 3-5 ) leads to a functional desensitization of the A 1 receptors. This phenomenon has already been described after chronic exposure to various A 1 receptor agonists such as R-PIA and N6-cyclopentyladenosine (Abbracchio et al., 1992; Lee et al., 1993) . Additionally, such stimulations can also result in a desensitization characterized by a loss of G i␣ -protein expression (Longabaugh et al., 1989) . Surprisingly, Von Lubitz et al. (1999) reported a protective effect of ADAC against ischemia in gerbils after chronic treatment for 60 d. This suggests that under their conditions, ADAC did not downregulate or desensitize the A 1 receptors. The reasons for this discrepancy with our data are elusive. It remains possible, however, that the pharmacokinetics of ADAC or the mechanisms of A 1 receptor desensitization may be species dependent. Nevertheless, despite profound A 1 receptor downregulation, the chronic treatment with ADAC did not increase the neurotoxic effects of 3NP. Therefore, ADAC does not produce any regimendependent inversion of the beneficial effect as reported previously for other A 1 agonists (Von Lubitz et al., 1994a,b; Jacobson et al., 1996) .
The fact that the first injection of ADAC in the 3NP/ADAC 3-5 group did not reduce the neurological score of the animals as compared with the 3NP/vehicle group suggests also that the development of motor symptoms 4 d after minipump implantation is probably not caused by a modulation of glutamate or dopamine release within the striatum. It could likely reflect intrinsic, striatal, metabolic alterations as suggested by the early decrease in striatal N-acetylaspartate level and zif-268 mRNA expression induced by 3NP Blum et al., 2002) .
In conclusion, our results provide the first demonstration that A 1 receptor activation is able to delay the development of striatal lesions as well as the worsening of motor disabilities in a rat model of Huntington's disease. This is of particular interest given the lack of pharmacological therapy for this neurological affection. Although the absence of a beneficial effect of ADAC after more than two injections precludes a direct application at the therapeutic level, the present strategy clearly deserve further evaluation to assess whether (1) post-lesional administration of ADAC or spaced short treatments at different times after the onset of degeneration would also be beneficial and (2) ADAC or related compounds may have functional effects in transgenic mice models of HD.
